株洲千金药业股份有限公司收购报告书2026年一季度持续督导意见——投资者应关注的关键内容
一、收购进展及资产过户情况
本报告书详细披露了株洲市国有资产投资控股集团有限公司（株洲国投）及其一致行动人对株洲千金药业股份有限公司（千金药业）的收购进展。收购完成后，株洲国投在千金药业的持股比例已超过30%，符合《上市公司收购管理办法》的免于发出要约收购条件。株洲国投承诺36个月内不转让认购股份，并已获得股东大会非关联股东批准，相关议案均顺利通过。
二、信息披露及监管合规
千金药业和相关各方严格履行了信息披露义务，自2024年8月27日开始至2025年10月，密集披露了包括停牌公告、交易进展、法律意见、审计报告、评估报告、独立财务顾问意见、内幕信息知情人自查报告、资产过户情况等多份公告和法律文件。收购相关股份已完成发行，工商变更登记也于2025年10月完成，收购已正式结束。
三、公司治理与规范运作
收购人及一致行动人严格遵守法律、行政法规和证券监管规则，依法规范行使股东权利。上市公司按照《公司法》《证券法》及中国证监会、上海证券交易所相关要求进行规范运作。本期内未发现违规情况。
四、承诺事项履行情况
株洲国投及一致行动人已严格履行所有公开承诺，包括信息真实性、股份锁定、业绩补偿、保持上市公司独立性、规范关联交易、避免同业竞争以及无减持计划等。未发现违约情形。
五、后续计划落实情况——对投资者的影响
- 主营业务调整： 收购人未改变或计划改变千金药业主营业务。
- 资产、业务处置或重组： 除本次收购外，未对资产进行重大处置、合并或重组，也无相关计划。
- 董事会和高管变动： 2026年1月选举新董事许大为，2026年2月董事谢爱维因治理结构调整辞职，职工代表罗勇补选为董事。变动均合规且已披露，未来无进一步调整计划。
- 章程条款修改： 本期内未对可能阻碍收购上市公司控制权的章程条款进行修改，亦无修改计划。
- 员工聘用重大变动： 未对现有员工聘用计划作重大变动，也无相关计划。
- 分红政策调整： 未对分红政策进行重大调整，也无相关计划。
- 业务和组织结构重大调整： 未进行重大调整，也无相关计划。
上述事项均按照《收购报告书》承诺和法律法规规定履行了必要程序和信息披露义务。
六、约定义务履行情况
收购人及一致行动人不存在未履行其他约定义务的情形。
投资者关注要点及潜在价格敏感信息
- 收购已完成，控股权稳固。 株洲国投实现对千金药业控股，未来三年不会转让新认购股份，控股权变动风险较低。
- 公司治理结构调整。 董事会人员变动虽合规，但请关注治理结构变化及其对公司战略影响。
- 未有重大业务、资产、分红、员工、组织结构调整计划。 经营方向较为稳定，暂时不存在因收购导致的重大变动或不确定性。
- 密集信息披露及合规操作。 有助于提升公司透明度和市场信心。
整体来看，收购完成、控股权稳定、公司治理合规、业务方向未变，短期内不会引发重大经营变动或市场不确定性。投资者可关注董事会变化及未来潜在战略调整，但目前并无明显价格敏感事件。
免责声明
本文内容仅供参考，不构成投资建议。投资者须结合自身情况、市场环境及其他公开信息作出决策。本文信息来源于公司官方公告及持续督导报告，未做任何增删或推测。
ZHUZHOU QIANJIN PHARMACEUTICAL CO., LTD. ACQUISITION REPORT Q1 2026 CONTINUING SUPERVISION OPINION — KEY POINTS FOR INVESTORS
1. Acquisition Progress and Asset Transfer
Zhuzhou State-owned Asset Investment Holding Group Co., Ltd. (Zhuzhou Guotou) and its concerted parties have completed their acquisition of Zhuzhou Qianjin Pharmaceutical Co., Ltd. (Qianjin Pharmaceutical), raising their shareholding above 30%. The acquisition qualifies for a waiver from a mandatory tender offer as per regulations, as Guotou has pledged not to transfer the subscribed shares for 36 months and obtained approval from non-related shareholders at the shareholders’ meeting.
2. Information Disclosure and Regulatory Compliance
Qianjin Pharmaceutical and related parties have strictly fulfilled their information disclosure obligations. From August 27, 2024, to October 2025, multiple announcements and legal documents were published, including suspension notices, transaction progress, legal opinions, audit and appraisal reports, independent financial advisor opinions, insider trading self-checks, and asset transfer status. The shares involved in the acquisition have been issued, the business registration changed, and the acquisition is officially completed.
3. Corporate Governance and Standard Operation
The acquirer and its concerted parties exercised shareholder rights in compliance with laws, regulations, and exchange rules. The listed company operated according to the Company Law, Securities Law, CSRC, and Shanghai Stock Exchange requirements. No violations were found during the reporting period.
4. Fulfillment of Commitments
Zhuzhou Guotou and its concerted parties fully honored all public promises, including information authenticity, share lock-up, performance compensation, maintaining company independence, regulating related-party transactions, avoiding competition, and no reduction plan. No breaches were detected.
5. Implementation of Subsequent Plans — Impact for Investors
- Main Business Adjustment: No change or plan to change Qianjin Pharmaceutical’s main business.
- Asset/Business Disposal or Restructuring: No major asset disposals, mergers, or restructuring plans except this acquisition.
- Board/Senior Management Change: In January 2026, new director Xu Dawei was elected; in February, director Xie Aiwei resigned due to governance adjustment, and Luo Yong was elected as employee director. All changes were legal and disclosed; no further plans are in place.
- Articles of Association Modification: No changes made or planned to provisions that may hinder control.
- Major Employee Changes: No significant changes or plans regarding employee arrangements.
- Dividend Policy Adjustment: No major changes or plans regarding dividend policy.
- Major Business/Organizational Adjustment: No major adjustments made or planned to business or organizational structure.
All these matters followed the Acquisition Report commitments and legal procedures.
6. Fulfillment of Other Agreed Obligations
No other agreed obligations were found unfulfilled during the acquisition.
Investor Highlights and Potential Price-Sensitive Information
- Acquisition Completed, Control Stable: Zhuzhou Guotou now firmly controls Qianjin Pharmaceutical, with no transfer of new shares for three years, reducing control change risk.
- Corporate Governance Adjustments: Board changes, while compliant, merit attention for potential strategic impact.
- No Major Business, Asset, Dividend, Employee, or Organizational Changes Planned: Direction remains stable; no significant uncertainty from the acquisition.
- Intensive Information Disclosure and Compliance: Enhances transparency and market confidence.
Overall, the completed acquisition, stable control, compliant governance, and unchanged business direction mean no short-term major operational changes or uncertainties. Investors should monitor board changes for potential future strategy shifts, but no clear price-sensitive event exists at present.
Disclaimer
This article is for reference only and does not constitute investment advice. Investors should make decisions in consideration of their circumstances, market environment, and other public information. This information is sourced from official announcements and the continuing supervision report, without any additions or speculation.
